Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 488 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
488 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with progressing advanced or metastatic CLDN1-positive colorectal, intrahepatic cholangiocarcinoma, squamous non-small cell lung, urothelial, or cervical squamous cancers after standard systemic therapy receive intravenous ALE.P03 monotherapy. ALE.P03 is an investigational CLDN1-targeted antibody–drug conjugate that delivers exatecan, a topoisomerase I inhibitor, to CLDN1-expressing cells.
ClinicalTrials.gov ID: NCT07169734
TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors who have exhausted standard treatment options or have no standard therapy receive intravenous TJ101, a bispecific antibody-drug conjugate targeting EGFR and B7-H3, every 21 days. Prior topoisomerase I inhibitor treatment is excluded.
ClinicalTrials.gov ID: NCT07181473
TrialFetch AI summary: Patients with previously treated, progressive advanced or metastatic colorectal adenocarcinoma, non-small cell lung cancer, or pancreatic ductal adenocarcinoma who have no tolerable standard treatment options receive intravenous PHN-012, an investigational antibody–drug conjugate. Its target antigen and payload have not been disclosed.
ClinicalTrials.gov ID: NCT07127874
TrialFetch AI summary: Patients with advanced or metastatic MUC-1–overexpressing solid tumors after standard therapy receive M0324 alone or with pembrolizumab; the pembrolizumab cohort also requires progression on or after prior checkpoint inhibition. A separate cohort with previously untreated metastatic pancreatic ductal adenocarcinoma receives M0324 plus mFOLFIRINOX. M0324 is an investigational MUC-1 × CD40 bispecific antibody designed to activate immune cells near MUC-1–expressing tumors.
ClinicalTrials.gov ID: NCT07166601
TrialFetch AI summary: Adults with unresectable locally advanced or metastatic HCC, ECOG 0–1, and Child-Pugh A liver function receive ZW251, an investigational glypican-3–targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor payload. The study evaluates escalating and recommended doses for safety and preliminary antitumor activity.
ClinicalTrials.gov ID: NCT07164313
TrialFetch AI summary: Adults with measurable, homozygous MTAP-deleted solid tumors and ECOG performance status 0–1 receive oral BAY 3713372, an investigational PRMT5 inhibitor designed to target the PRMT5–MTA complex. Expansion cohorts include non–small cell lung and pancreatic ductal adenocarcinomas and may test BAY 3713372 with unspecified combination partners.
ClinicalTrials.gov ID: NCT06914128
TrialFetch AI summary: Adults with previously treated metastatic or recurrent lung adenocarcinoma, a drainable malignant pleural effusion, and FRα expression in at least 10% of tumor cells receive cyclophosphamide/fludarabine lymphodepletion followed by a single intrapleural infusion of autologous MOv19-BBz CAR T cells. The CAR T cells target folate receptor alpha on tumor cells.
ClinicalTrials.gov ID: NCT07116057
TrialFetch AI summary: Adults with previously treated, advanced DLL3-expressing small-cell lung cancer are eligible; selected cohorts also include lung large-cell neuroendocrine carcinoma, neuroendocrine prostate cancer, and gastroenteropancreatic neuroendocrine carcinoma. All receive ²²⁵Ac-ETN029, a DLL3-binding peptide designed to deliver alpha radiation to tumors; some also receive ¹¹¹In-ETN029 for SPECT/CT imaging.
ClinicalTrials.gov ID: NCT07006727
TrialFetch AI summary: Adults with progressing or recurrent small cell lung cancer, pulmonary large-cell neuroendocrine carcinoma, or extrapulmonary neuroendocrine carcinoma after prior systemic therapy (or when standard second-line therapy is unsuitable) receive [203Pb]Pb-MP0712 imaging followed by [212Pb]Pb-MP0712, a DLL3-binding DARPin that delivers alpha radiation to tumors. DLL3-positive imaging is required for extrapulmonary disease and for lung tumors in dose expansion.
ClinicalTrials.gov ID: NCT07278479
TrialFetch AI summary: Adults with relapsed or refractory, locally advanced or metastatic solid tumors harboring a SMARCA4 loss-of-function mutation receive once-daily oral PLX-61639 after approved treatment options have been exhausted or deemed unsuitable. PLX-61639 is an investigational degrader that recruits DCAF16 to eliminate SMARCA2, a protein on which SMARCA4-deficient tumors may depend.
ClinicalTrials.gov ID: NCT07284186